ArticleTranslational andrology and urology2025
Pre-treatment C-reactive protein level is a prognostic marker of patients treated with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: C-reactive protein (CRP) is one of the most important markers reflecting systemic inflammatory response. The objective of this study was to evaluate the prognostic value of CRP in patients undergoing treatment with immune checkpoint inhibitor (ICI) for renal cell carcinoma. Methods: We performed a systematic search of PubMed, Cochrane Library, and Web of Science databases in July 2024, following the PRISMA statement. A pooled meta-analysis was conducted to assess the prognostic value of CRP. We also evaluated the prognostic values of CRP kinetics. Results: The search identified 12 non-randomized controlled trials (NRCTs), of which 7 assessed the prognostic value of CRP and 5 evaluated CRP kinetics. Higher CRP level before treatment with ICI was a predictor of overall survival (OS) [hazard ratio (HR): 3.97, 95% confidence interval (CI): 2.27-6.94]. In a subgroup of patients treated with nivolumab alone, the pooled HR of OS and progression-free survival (PFS) was HR: 5.67, 95% CI: 2.12-15.12 and HR: 1.62, 95% CI: 1.01-2.61, respectively. "CRP flare-responders" defined as having CRP elevation of at least double the baseline during the first month after ICI-initiation followed by a decrease below the baseline within 2 months and "CRP-responders" defined as having a decrease in CRP levels of at least 30% from baseline within 3 months, did not show significantly better prognosis regarding PFS. Conclusions: Pre-treatment CRP level may stand as a good prognostic indicator in patients receiving ICI for renal cell carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.